GW Pharmaceuticals Limited is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols which was the first natural cannabis plant derivative to gain market approval in any country. Wikipedia
Parent organizations: Jazz Pharmaceuticals and Jazz Pharmaceuticals UK Holdings Limited
Founders: Geoffrey Guy and Brian Whittle
Headquarters: Cambridge, United Kingdom
Subsidiaries: Greenwich Biosciences, Inc., GW Research Ltd, Jazz Pharmaceuticals Research UK Limited, and more
Revenue: 527 million USD (2020)
Founded: 1998
Symbol: GWPH
Source: S&P Global Market Intelligence